Montelukast, Leukotriene CysLT1 antagonist; GPR17 antagonist (TBI2597)

Description

Product Details

Formal Name: 2-[1-[[(1R)-1-[3-[(E)-2-(7-Chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl]sulfanylmethyl]cyclopropyl]acetate, sodium salt

Alternate Names: MK-0476

Molecular Formula: C₃₅H₃₅ClNO₃S Na

Formula Weight: 608.17

CAS Number: 151767-02-1

Purity: >98%

Formulation: powder

Solubility: Soluble in DMSO (up to 60 mg/ml), in Water (up to 30 mg/ml) or in Ethanol (up to 60 mg/ml)

Storage: -20°C

Stability: ≥ 1 year.

 

Applications

Leukotriene  CysLT1 antagonist; GPR17 antagonist

 

Functions

Potent, selective CysLT1 receptor (leukotriene D4) antagonist (Ki = 0.18 nM). Displays anti-inflammatory and anti-asthmatic effects. Clinically useful agent for treatment of chronic asthma. Attenuates chronic brain injury after focal cerebral ischemia in rodent models. Decreases blood brain barrier dysfunction in mouse models. Blockade of GPR17 by montelukast elevates neural stem and progenitor proliferation.

 

Application Procedures

First dissolved in DMSO (up to 60 mg/ml), in Water (up to 30 mg/ml) or in Ethanol (up to 60 mg/ml), then diluted to aqueous buffer. Solutions in DMSO, distilled water, or ethanol may be stored at -20°C for up to 1 month.

Additional information

SIZE (mg)	250 MG, 50 MG

TBI2597_Montelukast